RethinkPeptides
ArticlesTopicsResearch

GLP-1 Safety

4 articles in this topic.

GLP-1 Safety

GLP-1 Agonists and Pancreatitis: The Evidence

A meta-analysis of 62 RCTs found a small pancreatitis signal with GLP-1 drugs that vanished when accounting for co-medications. Here is what the data shows.

13 min read|Mar 22, 2026
GLP-1 Safety

GLP-1 Agonists and Retinopathy

Semaglutide raised retinopathy concerns in SUSTAIN-6, but the risk appears tied to rapid glucose lowering, not the drug itself. Here is the full evidence.

13 min read|Mar 22, 2026
GLP-1 Safety

GLP-1 Agonists and Thyroid Cancer Risk

GLP-1 receptor agonists cause thyroid C-cell tumors in rodents but human evidence remains conflicting. Seven studies reveal what the data actually shows.

13 min read|Mar 22, 2026
GLP-1 Safety

Gastroparesis and GLP-1 Drugs: The Evidence

GLP-1 agonists delay gastric emptying by design. When does slowed digestion cross into gastroparesis, how common is it, and what the anesthesia data shows.

13 min read|Mar 21, 2026

RethinkPeptides

Evidence-based peptide education. No hype, no sales. Just science.

Navigate

All ArticlesTopicsResearch DatabaseEvidence MethodologyDownload DataSearch

About

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of Use

Disclaimer

Content on RethinkPeptides is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Peptides discussed here may not be approved for human use in your jurisdiction.

© 2026 RethinkPeptides. All rights reserved.